Absci Announces Collaboration with Oracle Cloud Infrastructure and AMD to Enhance Generative AI-Driven Drug Discovery

Absci collaborates with Oracle Cloud and AMD to enhance AI-driven drug discovery and biologics design capabilities.

Quiver AI Summary

Absci, a clinical-stage biotech company focused on advancing drug discovery through generative AI, has announced a collaboration with Oracle Cloud Infrastructure (OCI) and AMD to enhance its AI-driven drug creation platform. This partnership aims to accelerate the biologics design process by utilizing OCI's advanced AI infrastructure and AMD's cutting-edge hardware, including the latest Instinct™ MI355X GPUs. With this collaboration, Absci can expedite large-scale molecular dynamics simulations and end-to-end antibody design, significantly improving the speed and efficiency of drug discovery. Absci's efforts align with its mission to innovate therapeutic development and bring better treatments to patients faster, while tapping into the high-performance capabilities offered by both OCI and AMD's technologies.

Potential Positives

Absci has announced a collaboration with Oracle Cloud Infrastructure and AMD, enhancing its capabilities in generative AI-driven drug discovery.
The partnership enables Absci to accelerate its biologics design cycles and improve the efficiency of its AI Drug Creation Platform.
Utilizing OCI's advanced infrastructure and AMD's cutting-edge GPUs, Absci can conduct large-scale molecular-dynamics simulations, leading to faster and more precise therapeutic designs.
This collaboration positions Absci to significantly improve the pace of bringing novel therapeutics to patients by leveraging state-of-the-art technology in drug discovery.

Potential Negatives

Absci may be viewed as overly reliant on external partnerships with OCI and AMD for its drug discovery processes, which could raise concerns about its own technological independence and capabilities.
The press release lacks specific details on the terms of the collaboration with OCI and AMD, potentially leading to questions about the long-term viability and strategic alignment of this partnership.
Absci's emphasis on AI-driven processes might lead to skepticism in the biotech industry regarding the efficacy and safety of AI-generated therapeutics compared to traditional methods.

FAQ

What is Absci's recent collaboration about?

Absci announced a partnership with Oracle Cloud Infrastructure and AMD to enhance generative AI-driven drug discovery for biologics.

How does OCI contribute to Absci's drug creation platform?

OCI provides the AI infrastructure that helps Absci accelerate the development of its AI Drug Creation Platform, enabling large-scale simulations.

What technology is AMD providing for this collaboration?

AMD is supplying its next generation Instinct™ MI355X GPUs to improve performance and scalability for Absci's drug discovery workflows.

What are the benefits of using OCI's bare metal instances?

OCI's bare metal instances reduce latency and increase throughput, which is essential for large-scale model training and molecular-dynamics simulations.

How does Absci’s approach enhance drug discovery?

Absci combines advanced AI algorithms with wet lab validation to rapidly design innovative therapeutics and improve precision in drug discovery.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$ABSI Insider Trading Activity

$ABSI insiders have traded $ABSI stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $ABSI stock by insiders over the last 6 months:

ANDREAS BUSCH (Chief Innovation Officer) purchased 50,000 shares for an estimated $152,000

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$ABSI Hedge Fund Activity

We have seen 71 institutional investors add shares of $ABSI stock to their portfolio, and 79 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

VANGUARD GROUP INC added 1,763,909 shares (+37.6%) to their portfolio in Q2 2025, for an estimated $4,533,246
BLACKROCK, INC. added 1,576,757 shares (+23.2%) to their portfolio in Q2 2025, for an estimated $4,052,265
WOODLINE PARTNERS LP added 1,574,861 shares (+113.2%) to their portfolio in Q2 2025, for an estimated $4,047,392
MERCK & CO., INC. removed 998,163 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,505,389
CITADEL ADVISORS LLC removed 953,579 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,450,698
ARK INVESTMENT MANAGEMENT LLC removed 909,161 shares (-8.3%) from their portfolio in Q2 2025, for an estimated $2,336,543
MILLENNIUM MANAGEMENT LLC removed 845,167 shares (-78.6%) from their portfolio in Q2 2025, for an estimated $2,172,079

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ABSI Analyst Ratings

Wall Street analysts have issued reports on $ABSI in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 08/13/2025
Morgan Stanley issued a "Overweight" rating on 07/28/2025
Keybanc issued a "Overweight" rating on 04/16/2025
Guggenheim issued a "Buy" rating on 03/20/2025
HC Wainwright & Co. issued a "Buy" rating on 03/19/2025

To track analyst ratings and price targets for $ABSI, check out Quiver Quantitative's $ABSI forecast page.

$ABSI Price Targets

Multiple analysts have issued price targets for $ABSI recently. We have seen 5 analysts offer price targets for $ABSI in the last 6 months, with a median target of $8.0.

Here are some recent targets:

Vikram Purohit from Morgan Stanley set a target price of $5.89 on 08/18/2025
Gil Blum from Needham set a target price of $8.0 on 08/13/2025
Scott Schoenhaus from Keybanc set a target price of $9.0 on 04/16/2025
Vamil Divan from Guggenheim set a target price of $10.0 on 03/20/2025
Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $7.0 on 03/19/2025

Full Release

AUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Absci , a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with Oracle Cloud Infrastructure (OCI) and AMD to accelerate generative AI-driven drug discovery. Absci’s generative AI Drug Creation Platform leverages OCI’s AI infrastructure and AMD’s latest hardware, enabling it to consolidate its infrastructure and accelerate its biologics design cycles.

To advance Absci’s mission of creating better biologics for patients more quickly, Absci has selected OCI as the technical foundation for developing AI models and scaling AI workflows. With OCI, Absci has been able to accelerate the development and operations of its AI Drug Creation Platform, including large‑scale molecular‑dynamics (MD) simulations and end‑to‑end antibody design. Absci is building on this success with OCI and partnering with AMD to further boost the performance and scalability of its AI Drug Creation Platform with AMD’s next generation Instinct™ MI355X GPUs.

“Our mission is to push the boundaries of how we design new therapeutics,” said Sean McClain, Founder and CEO, Absci. “With OCI and AMD, we are pairing our cutting-edge AI models with best‑in‑class infrastructure. This collaboration accelerates our ability to bring novel therapeutics to patients while laying the technical foundation for the next generation of AI‑powered drug‑discovery workflows.”

Scaling AI-driven drug discovery with OCI and AMD

OCI’s bare metal instances, powered by 5th Generation AMD EPYC™ processors and ultrafast RDMA cluster networking, give Absci the low-latency networking and throughput needed for large-scale model training and high-resolution molecular-dynamics simulations that refine antibody–antigen interactions. With direct, bare-metal access to AMD GPUs in a single, flat-network supercluster, Absci has been able to eliminate hypervisor overhead, reduce inter-GPU latency to as little as 2.5 µs, and benefit from terabytes-per-second throughput for checkpointing and data streaming.

“Absci’s generative AI-driven drug discovery is the kind of breakthrough workflow OCI was built for,” said Dan Spellman, vice president, AI and OCI, Healthcare & Life Sciences, Oracle. “By combining bare metal GPUs, OCI Compute E6 instances, ultrafast RDMA networking, and high-performance storage, we’re providing the predictable performance and close engineering collaboration Absci needs to push the boundaries of biologics design.”

“Absci is demonstrating how AI can transform the pace of drug discovery, and we’re proud to support that mission,” said Ram Peddibhotla, corporate vice president, Data Center GPU Cloud Business, AMD. “By combining OCI with AMD EPYC CPUs, AMD Instinct GPUs and our open ROCm software platform, this collaboration provides the performance and scalability needed to advance complex biologics design and support more efficient discovery workflows.”

About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn ( @absci ), X ( @Abscibio ) and YouTube .

About AMD
For more than 55 years AMD has driven innovation in high-performance computing, graphics and visualization technologies. Billions of people, leading Fortune 500 businesses and cutting-edge scientific research institutions around the world rely on AMD technology daily to improve how they live, work and play. AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ:AMD) website , blog , LinkedIn , Facebook and X pages.

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com .

Trademarks
AMD, EPYC, AMD Instinct, ROCm and combinations thereof are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.

Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

Contact Info
Absci
[email protected]

David Szabados
AMD Communications
[email protected]

Julia Allyn
Oracle
[email protected]